Is Alignment Healthcare (ALHC) Fairly Priced After Recent 1 Year Share Price Surge

Simply Wall St

Wed, February 11, 2026 at 3:14 PM GMT+9 6 min read

In this article:

•                                       StockStory Top Pick 
  

  ALHC

  -0.63%

Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge.

If you are wondering whether Alignment Healthcare's share price matches its underlying value, you are not alone. This article will help you connect the current price with what the business may be worth.

The stock closed at US$20.63 recently, with returns of a 9.9% decline over the past 7 days, a 0.7% decline over 30 days, 2.0% year to date, 43.5% over 1 year and 89.1% over 3 years.

Recent coverage around Alignment Healthcare has focused on its position in the Medicare Advantage space and its efforts to grow membership and manage medical costs. This backdrop helps explain why investors have been reassessing the stock. News flow has also highlighted broader interest in value based care models, which can shift how the market thinks about risk and growth for companies like Alignment Healthcare.

On Simply Wall St's valuation checklist, Alignment Healthcare scores 4 out of 6 for being assessed as undervalued. Next we will compare different valuation approaches before finishing with a way to look beyond the numbers to understand what that score really means.

Alignment Healthcare delivered 43.5% returns over the last year. See how this stacks up to the rest of the Healthcare industry.

Approach 1: Alignment Healthcare Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model takes the cash Alignment Healthcare is expected to generate in the future and then discounts those projections back into today’s dollars to estimate what the business might be worth right now.

For Alignment Healthcare, Simply Wall St uses a 2 Stage Free Cash Flow to Equity model based on cash flow projections. The latest twelve month free cash flow is about $132.5 million. Analysts provide estimates for the next few years, and beyond that Simply Wall St extrapolates cash flows, reaching projected free cash flow of about $181.1 million in 2035, all in $.

When all those projected cash flows are discounted back, the model arrives at an estimated intrinsic value of about $18.60 per share. Compared with the recent share price of $20.63, the DCF output suggests the stock is around 10.9% overvalued on this set of assumptions.

Result: OVERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Alignment Healthcare may be overvalued by 10.9%. Discover 51 high quality undervalued stocks or create your own screener to find better value opportunities.

ALHC Discounted Cash Flow as at Feb 2026

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Alignment Healthcare.

繼續閱讀  

Approach 2: Alignment Healthcare Price vs Sales

For companies where earnings are not the main focus, the P/S ratio can be a useful way to think about value because it compares the share price with the revenue the business generates, rather than profits that can swing around with accounting or one off items.

What counts as a reasonable P/S ratio often reflects how the market views a company’s growth potential and risk. Higher growth expectations or lower perceived risk can justify a higher multiple, while slower expected growth or higher uncertainty can point to a lower one.

Alignment Healthcare currently trades on a P/S ratio of 1.13x. That sits below the Healthcare industry average of 1.25x and the peer average of 1.73x. Simply Wall St also calculates a Fair Ratio of 1.17x for Alignment Healthcare. This Fair Ratio is a proprietary view of what the P/S ratio could be, given factors such as earnings growth, profit margin, industry, market cap and company specific risks.

Compared with simple industry or peer comparisons, the Fair Ratio aims to be more tailored because it folds in those business specific factors rather than just grouping Alignment Healthcare with broad peers.

Since the Fair Ratio of 1.17x is very close to the current 1.13x, the shares look ABOUT RIGHT on this measure.

Result: ABOUT RIGHT

NasdaqGS:ALHC P/S Ratio as at Feb 2026

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 23 top founder-led companies.

Upgrade Your Decision Making: Choose your Alignment Healthcare Narrative

Earlier we mentioned that there is an even better way to understand valuation. On Simply Wall St’s Community page you can use Narratives, which are short, clear stories that link your view of Alignment Healthcare’s future revenue, earnings and margins to a financial forecast. This is then turned into a Fair Value you can compare with the current share price to help you decide whether the stock looks attractive or stretched. Your view is then automatically updated as new information such as earnings or news comes in. For example, one investor might build an optimistic Alignment Healthcare Narrative that lines up with a Fair Value around US$30, while another might prefer a more cautious Narrative closer to US$18. You can see both side by side and decide which story and valuation best match your own expectations.

For Alignment Healthcare, we will make it really easy for you with previews of two leading Alignment Healthcare Narratives:

🐂 Alignment Healthcare Bull Case

Fair Value: US$30.00

Implied undervaluation vs last close: around 31.2%

Revenue growth assumption: 36.40%

Analysts in this camp expect strong membership growth, member retention and scalable operations to support higher long term revenue and earnings.

They see operating leverage from a low SG&A ratio, automation and AI, with margins and earnings modeled to improve over several years.

The Fair Value of US$30.00 reflects these higher earnings and margin assumptions, as well as a higher future P/E multiple than the industry level cited.

🐻 Alignment Healthcare Bear Case

Fair Value: US$18.00

Implied overvaluation vs last close: around 14.6%

Revenue growth assumption: 28.14%

This view puts more weight on regulatory and reimbursement risk in Medicare Advantage, as well as potential margin pressure from medical costs.

It also highlights thin margins, negative free cash flow and possible reliance on external financing if medical cost trends or audits move against the company.

The Fair Value of US$18.00 assumes slower earnings progress and a lower earnings base, even though it still uses a relatively high future P/E multiple.

Putting these side by side gives you a clear spread of outcomes, from a bullish Fair Value above US$30.00 to a more cautious Fair Value of US$18.00. Both are anchored in explicit revenue, margin and P/E assumptions. Your next step is to decide which story feels closer to how you see Alignment Healthcare executing from here, and whether the current price of US$20.63 compensates you for the risks those narratives outline.

Do you think there’s more to the story for Alignment Healthcare? Head over to our Community to see what others are saying!

NasdaqGS:ALHC 1-Year Stock Price Chart

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include ALHC.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

條款 及 私隱政策

Privacy Dashboard

More Info